Peter P. Yu, MD, Elected ASCO President, 2014–2015, Others Named to ASCO Board

Get Permission

Peter P. Yu, MD, has been elected President of ASCO for a 1-year term beginning in June 2014. He will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2013. Additionally, three new members were elected to the ASCO Board of Directors, and three new members were elected to the ASCO Nominating Committee.

“I am both honored and privileged by the opportunity to lead ASCO,” said Dr. Yu. “I have been fortunate to serve the Society for many years in a volunteer capacity, and in doing so, have developed a depth and breadth of knowledge and experience on issues that are important for the advancement of cancer science and care. As President of the Society, I look forward to working collaboratively with the membership, staff, and Board of Directors to further advance the ASCO mission and vision.”

Career Highlights

Dr. Yu is currently the Director of Cancer Research at Palo Alto Medical Foundation. He received his medical degree from Brown University, and performed his internship and residency in Internal Medicine at St. Luke’s-Roosevelt Hospital and a fellowship in Neoplastic Diseases at Mount Sinai Hospital. Dr. Yu was also a Research Fellow and Associate at Memorial Sloan-Kettering Cancer Center. Dr. Yu is well known for his knowledge and understanding of how health information technology can advance the prevention, diagnosis, and treatment of cancer care.

Since joining ASCO in 1986, Dr. Yu has served on the Quality of Care, Cancer Research, and Clinical Practice Committees, the Health Information Technology Workgroup (current Chair), Integrated Media and Technology Committee, and Board of Directors, among others. He was also previously the ASCO State Affiliate Society President of the Association of Northern California Oncologists and is currently an active blogger on

Newly Elected ASCO Board Members

ASCO’s Board of Directors comprises oncology leaders who are elected to positions reflecting various specialties within the oncology field. The following physicians will begin 3-year terms as members of ASCO’s Board of Directors starting in June 2013:

Therese M. Mulvey, MD, FASCO, has been elected to one of the Community Oncologist seats. Dr. Mulvey is the Physician-in-Chief at Southcoast Centers for Cancer Care, part of Southcoast Health System, with centers in Fairhaven and Fall River, Massachusetts. An active member since 2001, she currently serves on ASCO’s Quality of Care Committee, Clinical Practice Committee, and the Cost of Cancer Care Task Force. Dr. Mulvey has been a Fellow of ASCO since 2010.

Neal J. Meropol, MD, has been elected to the Medical Oncologist seat. Dr. Meropol is a Professor of Medicine and Chief of the Division of Hematology and Oncology at University Hospitals Case Medical Center & Case Western Reserve University, Associate Director for Clinical Research at Case Comprehensive Cancer Center, Associate Director for Clinical Programs at University Hospitals Seidman Cancer Center, and the Dr. Lester E. Coleman, Jr. Endowed Chair in Cancer Research and Therapeutics. An ASCO member since 1993, he serves on the Cost of Care Task Force and Cancer Communications Committee, and Co-Chairs the ASCO/AACR Methods in Clinical Cancer Research workshop.

Paulo Marcelo Gehm Hoff, MD, PhD, FACP, has been elected to one of the Undesignated Specialty seats. Dr. Hoff is the Professor of Oncology and General Director of the ICESP-Instituto do Câncer do Estado de São Paulo, at the University of São Paulo, as well as General Director of the Oncology Center at the Hospital Sírio Libanês, Brazil. He is a voluntary faculty member at the University of Miami. An ASCO member since 1996, he currently serves on the Gastrointestinal Cancers Symposium Planning Committee.

Newly Elected Members of ASCO Nominating Committee

Three newly elected ASCO Nominating Committee members will serve 3-year terms beginning in June 2013:

Roscoe F. Morton, MD, FACP, has been elected to the Community Oncologist seat on the Nominating Committee. Dr. Morton is a partner at Medical Oncology and Hematology Associates of Iowa. He is also a Clinical Assistant Professor at the University of Iowa College of Medicine-Des Moines. Dr. Morton currently serves ASCO in numerous capacities including as Chair of the State Affiliate Working Group and a member of both the Clinical Practice Committee and the Special Awards Selection Committee.

Lee M. Ellis, MD, has been elected to one of the Undesignated Specialty seats on the Nominating Committee. Dr. Ellis is a Professor of Surgery and Cancer Biology at The University of Texas MD Anderson Cancer Center and is also the William C. Liedtke, Jr. Chair in Cancer Research. Dr. Ellis currently serves ASCO in numerous capacities including as Chair of the Cancer Research Committee and Track Leader, Tumor Biology of the Education Committee.

Kim Allyson Margolin, MD, has been elected to one of the Undesignated Specialty seats on the Nominating Committee. She will serve as the Chair of the Nominating Committee in 2015–2016. Dr. Margolin is an Associate Director for the Hematology-Oncology Fellowship and a Professor in the Division of Oncology at the University of Washington and Director of the University of Washington/Seattle Cancer Care Alliance clinical research program in melanoma and kidney cancer. Dr. Margolin has served on the ASCO Cancer Education Committee and Best of ASCO® Planning Committee. ■